Supplementary Figures 1 - 10 from Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
Richard J. Rickles(The University of Texas at San Antonio Health Science Center), Margaret Lee(University of Chicago), William Avery(Johnson & Johnson (United States)), Vikram Kansra(The University of Texas at San Antonio Health Science Center), Jennifer S. Carew(University of Arizona), David M. Crowe, Kenneth C. Anderson(Dana-Farber Cancer Institute), Alexis A. Borisy(The University of Texas at San Antonio Health Science Center), Winnie F. Tam(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona), Melissa Farwell(The University of Texas at San Antonio Health Science Center), Antoaneta S. Necheva(The University of Texas at San Antonio Health Science Center), Mei Chen(Guangzhou Medical University), Constantine Mitsiades, Laura Pierce(The University of Texas at San Antonio Health Science Center), Douglas W. McMillin(The University of Texas at San Antonio Health Science Center), Thomas P. Giordano(Baylor College of Medicine)
Cited by 0
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k